What does USP/EP/JP compliance mean for a gelatin supplier?

Beyond Biopharma · Pharmaceutical Gelatin FAQ

Compliance with USP, EP or JP does not mean there is one single global gelatin standard. It means that a given lot of gelatin, when tested to the methods and limits written in that specific pharmacopoeia's monograph for gelatin, satisfies them. The US Pharmacopeia (USP), the European Pharmacopoeia (EP) and the Japanese Pharmacopoeia (JP) each define their own monograph for gelatin, with partly overlapping but not identical tests and limits. When a supplier claims a batch is USP/EP/JP compliant, the practical question is which pharmacopoeias each batch is actually tested to and via which tests. Buyers should therefore ask whether a lot is released against USP alone, EP alone, JP alone, or several, request the certificate of analysis that reports the relevant monograph tests, and confirm that the specific monograph edition in force at the time of testing was used, because editions are revised over time.

Pharmacopoeias are regional rulebooks, not one standard

USP, EP and JP are the compendia of standards that governs medicines in the United States, Europe and Japan respectively. Each one publishes a monograph for gelatin (as well as for gelatin capsules and related products) that defines what acceptable gelatin is: its identity, the limits for impurities such as heavy metals, sulphur dioxide and peroxide, limits for microbiological quality and for proteinaceous contaminants, and method-specific tests. Because they are independent documents written by different bodies, a material can comfortably be within all three — or, if tested to one and not the others, carry a claim that only covers the ones actually run.

The practical meaning of a "USP/EP/JP compliant" claim

Compliance is tested per lot and per monograph. A truthful claim means a particular production lot was tested against the methods of the named pharmacopoeia edition and met its limit. It follows that:

• "USP compliant" and "EP compliant" describe separate release tests, even where the two monographs resemble each other.
• Listing "USP/EP/JP" together usually signals that the supplier routinely releases lots that pass all three, which is valued when one factory ships to markets governed by each compendium.
• A claim should not be taken to mean a single certificate describes one universal test, nor that every edition and every batch shares one standard without limits evolving.

Why monographs are keyed to specific editions

Each compendium is issued in editions — for example the USP chapters that apply at a point in time, the current EP, and the current JP. Production control is written against the edition in force. Monograph contents (limits, test methods, general chapters such as methods of bacterial endotoxins or disintegration) can be revised, so two batches made a year apart may be released against slightly different references. This is why your quality file should pin down which edition or publication in force was applied to the batch you received, alongside the numeric results on its COA.

How buyers should cut through the term

Compliance is one input among several

Passing a pharmacopoeia monograph is a necessary part of pharmaceutical suitability but usually not the whole story: a buyer also considers end-user regulatory filing, excipient quality expectations, and functional properties such as Bloom strength and viscosity for a given application. Where you are selecting a grade for a specific market, treat the pharmacopoeia claim as the eligibility layer and confirm filing and functional details with your regulatory and technical teams and the supplier.